AstraZeneca Sues US Over Drugs for Medicare Price Cuts Round 2

AstraZeneca Plc sued the US government over its determination of medicines eligible for the Medicare drug price negotiations, filing another challenge against the plan after one of its cancer treatments was picked for the program’s second cycle.

The complaint filed Dec. 19 in the US District Court for the District of Maryland alleges the Centers for Medicare & Medicaid Services acted unlawfully when it defined “qualifying single source drugs” under the Biden-era plan. The government selects qualifying single source drugs for the program, depending on how long they’ve been on the market. The drugs are high-cost, brand name products without ...